Unknown

Dataset Information

SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.


ABSTRACT:

Purpose

To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer.

Methods

Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 Gy in 15 fractions (fx), followed by 45 Gy/10 fx and, finally, 42.5 Gy/5 fx. Maximum combined CTV-PTV expansion was limited to 5 mm. Patients were treated on a Model G5 Cyberknife (Accuray, Sunnyvale, CA).

Results

Median follow-up is 13.4 months (range: 5.6-24.6 months), with 12 patients followed for at least one year. Maximum acute toxicity consisted of grade 2 hoarseness and dysphagia. Maximum chronic toxicity was seen in one patient treated with 45 Gy/10

SUBMITTER: Schwartz DL 

PROVIDER: S-EPMC5333979 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature